People · Operator
Named in public records as an officer, director or promoter · active 2018–2023 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Corvidia Therapeutics, Inc. | — | Biotechnology | Series C | $60.0M | $2.5B | 2018 |
| EIP Pharma, Inc. | — | Pharma | Series B | $44.1M | $8.3M | 2018 |
SYLVIE GREGOIRE at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside SYLVIE GREGOIRE on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Tyrell Rivers | 1 | 6 |
| Aaron Kantoff | 1 | 6 |
| William Turner | 1 | 4 |
| Marc De Garidel | 1 | 3 |
| Graziano Seghezzi | 1 | 3 |
| JOHN ALAM | 1 | 2 |
| Noel Donnelly | 1 | 1 |
| KARIM HELMY | 1 | 1 |
| RAM AIYAR | 1 | 1 |
| JEFF POULTON | 1 | 1 |
| FRANK ZAVRL | 1 | 1 |
| KELLY BLACKBURN | 1 | 1 |
| MARWAN SABBAGH | 1 | 1 |
| Tatjana May | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.